134 related articles for article (PubMed ID: 17003081)
1. Calcium channel blockers for primary Raynaud's phenomenon.
Ennis H; Hughes M; Anderson ME; Wilkinson J; Herrick AL
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD002069. PubMed ID: 26914257
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database.
Zaza P; Matthieu R; Jean-Luc C; Charles K
Br J Clin Pharmacol; 2020 Nov; 86(11):2217-2222. PubMed ID: 32337731
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.
Khouri C; Blaise S; Carpentier P; Villier C; Cracowski JL; Roustit M
Br J Clin Pharmacol; 2016 Jul; 82(1):6-16. PubMed ID: 26949933
[TBL] [Abstract][Full Text] [Related]
4. Ace inhibitors as a therapy for sarcopenia - evidence and possible mechanisms.
Sumukadas D; Witham MD; Struthers AD; McMurdo ME
J Nutr Health Aging; 2008; 12(7):480-5. PubMed ID: 18615230
[No Abstract] [Full Text] [Related]
5. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
Henness S; Wigley FM
Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.
Challenor VF
Drugs; 1994 Dec; 48(6):864-7. PubMed ID: 7533694
[TBL] [Abstract][Full Text] [Related]
7. Raynaud's Phenomenon: A Brief Review of the Underlying Mechanisms.
Fardoun MM; Nassif J; Issa K; Baydoun E; Eid AH
Front Pharmacol; 2016; 7():438. PubMed ID: 27899893
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of the human α2C-adrenergic receptor temperature-sensitive intracellular traffic.
Filipeanu CM; Pullikuth AK; Guidry JJ
Mol Pharmacol; 2015 May; 87(5):792-802. PubMed ID: 25680754
[TBL] [Abstract][Full Text] [Related]
9. Recent achievements in the management of Raynaud's phenomenon.
Baumhäkel M; Böhm M
Vasc Health Risk Manag; 2010 Apr; 6():207-14. PubMed ID: 20407628
[TBL] [Abstract][Full Text] [Related]
10. Raynaud's phenomenon (secondary).
Herrick A
BMJ Clin Evid; 2008 Sep; 2008():. PubMed ID: 19445801
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the renin-angiotensin-aldosterone system and cough.
Lacourcière Y; Lefebvre J
Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
[TBL] [Abstract][Full Text] [Related]
12. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
13. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
Jennings DL; Taber DJ
Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system mediators and Raynaud's phenomenon.
Wood HM; Ernst ME
Ann Pharmacother; 2006 Nov; 40(11):1998-2002. PubMed ID: 17003081
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
16. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
